Drug development is essentially a long, expensive bet: Ninety percent of drugs fail during clinical trials, goes one of the life science industry’s most oft-quoted statistics. But new ways of identifying and testing therapies, a more precise understanding of disease, and a renewed sense of urgency to address longstanding public health issues could change that dynamic, life science leaders argued this week.
A panel of biomedical experts at the Milken Institute 2024 Global Conference on Monday pointed to recent scientific breakthroughs as examples of what is possible, from the development of mRNA vaccines to the first-ever CRISPR-based therapy to receive regulatory approval. But they cautioned that the pace of future successes will depend on whether the industry can streamline and rethink drug development.
“We have as an industry accepted the notion that this is what it is. Frankly, our good friends in the pharmaceutical industry benefit from that,” said Noubar Afeyan, founder and CEO of venture capital firm Flagship Pioneering. “Going slow and having it [cost] a lot of money favors incumbents.”
Click this link for the original source of this article.
Author: Jonathan Wosen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.